CUSIP 02043Q107 · who reports it, how much, and how much it matters to them
44 of the 720 hedge fund managers we track reported shares of Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) on Form 13F for 30 June 2026. Between them they reported USD 2bn. The largest position belongs to Two Sigma Investments, at USD 565m. The manager with the most riding on it is Deep Track Capital, where it is 3.6% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Two Sigma Investments35 funds on PPLI.com | USD 565m | 0.4% |
| 2 | D. E. Shaw & Co.15 funds on PPLI.com | USD 332m | 0.2% |
| 3 | Deep Track Capital1 fund on PPLI.com | USD 248m | 3.6% |
| 4 | Polar Capital LLP26 funds on PPLI.com | USD 145m | 0.3% |
| 5 | Millennium Management6 funds on PPLI.com | USD 95m | 0.0% |
| 6 | Marshall Wace LLP84 funds on PPLI.com | USD 78m | 0.1% |
| 7 | Squarepoint Ops7 funds on PPLI.com | USD 70m | 0.1% |
| 8 | Citadel Advisors32 funds on PPLI.com | USD 58m | 0.0% |
| 9 | Capital Fund Management S.A.12 funds on PPLI.com | USD 47m | 0.2% |
| 10 | Hudson Bay Capital Management8 funds on PPLI.com | USD 45m | 0.1% |
| 11 | LMR Partners2 funds on PPLI.com | USD 40m | 0.2% |
| 12 | Bridgewater Associates45 funds on PPLI.com | USD 30m | 0.1% |
| 13 | Balyasny Asset Management25 funds on PPLI.com | USD 27m | 0.0% |
| 14 | Casdin Capital3 funds on PPLI.com | USD 23m | 1.1% |
| 15 | Rock Springs Capital Management2 funds on PPLI.com | USD 20m | 1.0% |
| 16 | Polymer Capital Management (HK)1 fund on PPLI.com | USD 20m | 1.0% |
| 17 | Jain Global1 fund on PPLI.com | USD 17m | 0.1% |
| 18 | J. Goldman & Co.1 fund on PPLI.com | USD 12m | 0.3% |
| 19 | Bronte Capital Management Pty3 funds on PPLI.com | USD 11m | 1.1% |
| 20 | 683 Capital Management2 funds on PPLI.com | USD 11m | 0.5% |
| 21 | Engineers Gate Manager1 fund on PPLI.com | USD 10m | 0.1% |
| 22 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 9.4m | 0.0% |
| 23 | IFM Investors Pty7 funds on PPLI.com | USD 8.9m | 0.1% |
| 24 | CIBC Asset Management69 funds on PPLI.com | USD 8.8m | 0.0% |
| 25 | Orbimed Advisors1 fund on PPLI.com | USD 5.1m | 0.1% |
| 26 | Aquatic Capital Management3 funds on PPLI.com | USD 4.7m | 0.2% |
| 27 | Campbell & Company Investment Adviser8 funds on PPLI.com | USD 3.4m | 0.2% |
| 28 | Sphera Funds Management1 fund on PPLI.com | USD 3.3m | 0.4% |
| 29 | Boothbay Fund Management2 funds on PPLI.com | USD 1.9m | 0.0% |
| 30 | Fora Capital1 fund on PPLI.com | USD 1.6m | 0.1% |
| 31 | Voleon Capital Management13 funds on PPLI.com | USD 1.6m | 0.0% |
| 32 | Voloridge Investment Management6 funds on PPLI.com | USD 1.4m | 0.0% |
| 33 | Cinctive Capital Management5 funds on PPLI.com | USD 995,000 | 0.0% |
| 34 | Walleye Capital8 funds on PPLI.com | USD 950,000 | 0.0% |
| 35 | Cannon Global Investment Management2 funds on PPLI.com | USD 753,000 | 2.1% |
| 36 | Brandywine Managers47 funds on PPLI.com | USD 698,000 | 0.3% |
| 37 | Graham Capital Management18 funds on PPLI.com | USD 679,000 | 0.0% |
| 38 | Capstone Investment Advisors25 funds on PPLI.com | USD 572,000 | 0.0% |
| 39 | Rangeley Capital6 funds on PPLI.com | USD 452,000 | 0.4% |
| 40 | Oxford Asset Management LLP2 funds on PPLI.com | USD 411,000 | 0.2% |
| 41 | Brevan Howard Capital Management39 funds on PPLI.com | USD 338,000 | 0.0% |
| 42 | Caxton Associates6 funds on PPLI.com | USD 287,000 | 0.0% |
| 43 | Dark Forest Capital Management2 funds on PPLI.com | USD 275,000 | 0.0% |
| 44 | The Quarry1 fund on PPLI.com | USD 191,000 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Deep Track Capital | USD 248m | 3.6% |
| 2 | Cannon Global Investment Management | USD 753,000 | 2.1% |
| 3 | Bronte Capital Management Pty | USD 11m | 1.1% |
| 4 | Casdin Capital | USD 23m | 1.1% |
| 5 | Polymer Capital Management (HK) | USD 20m | 1.0% |
| 6 | Rock Springs Capital Management | USD 20m | 1.0% |
| 7 | 683 Capital Management | USD 11m | 0.5% |
| 8 | Sphera Funds Management | USD 3.3m | 0.4% |
| 9 | Rangeley Capital | USD 452,000 | 0.4% |
| 10 | Two Sigma Investments | USD 565m | 0.4% |
Alnylam Pharmaceuticals, Inc. trades under the symbol ALNY on the Nasdaq. Its CUSIP, the code used on Form 13F, is 02043Q107.
44 of the 720 hedge fund managers PPLI.com tracks reported Alnylam Pharmaceuticals, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Two Sigma Investments (USD 565m), D. E. Shaw & Co. (USD 332m), Deep Track Capital (USD 248m), Polar Capital LLP (USD 145m) and Millennium Management (USD 95m).
44 managers in our coverage reported it, and between them they run 614 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Deep Track Capital, where the position was 3.6% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Alnylam Pharmaceuticals, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.